$4.02
10.27% yesterday
Nasdaq, Nov 20, 10:00 pm CET
ISIN
US92511W1080
Symbol
VRCA

Verrica Pharmaceuticals Inc Stock price

$4.02
-0.46 10.27% 1M
-2.41 37.49% 6M
-2.98 42.57% YTD
-4.85 54.70% 1Y
-20.48 83.59% 3Y
-90.58 95.75% 5Y
-170.98 97.70% 10Y
-170.98 97.70% 20Y
Nasdaq, Closing price Thu, Nov 20 2025
-0.46 10.27%
ISIN
US92511W1080
Symbol
VRCA
Industry

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
$22.8m
Cash
$15.4m
Shares outstanding
9.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
-18.2%
Return on Equity
776.7%
ROCE
-394.6%
ROIC
-
Debt/Equity
-2.2
Financials (TTM | estimate)
Revenue
$14.7m | $32.7m
EBITDA
$-38.3m | $-31.5m
EBIT
$-39.0m | $-15.1m
Net Income
$-48.7m | $-12.0m
Free Cash Flow
$-47.7m
Growth (TTM | estimate)
Revenue
5.7% | 332.2%
EBITDA
52.0% | 51.4%
EBIT
51.6% | 77.1%
Net Income
43.8% | 84.3%
Free Cash Flow
27.4%
Margin (TTM | estimate)
Gross
86.5%
EBITDA
-260.7% | -96.3%
EBIT
-265.4%
Net
-331.5% | -36.8%
Free Cash Flow
-324.2%
More
EPS
$-5.1
FCF per Share
$-5.2
Short interest
7.9%
Employees
71
Rev per Employee
$110.0k
Show more

Is Verrica Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

Verrica Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Verrica Pharmaceuticals Inc forecast:

7x Buy
64%
4x Hold
36%

Analyst Opinions

11 Analysts have issued a Verrica Pharmaceuticals Inc forecast:

Buy
64%
Hold
36%

Financial data from Verrica Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
15 15
6% 6%
100%
- Direct Costs 2 2
10% 10%
14%
13 13
9% 9%
86%
- Selling and Administrative Expenses 44 44
38% 38%
296%
- Research and Development Expense 7.70 7.70
62% 62%
52%
-38 -38
52% 52%
-261%
- Depreciation and Amortization 0.70 0.70
13% 13%
5%
EBIT (Operating Income) EBIT -39 -39
52% 52%
-266%
Net Profit -49 -49
44% 44%
-332%

In millions USD.

Don't miss a Thing! We will send you all news about Verrica Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Verrica Pharmaceuticals Inc Stock News

Neutral
Seeking Alpha
4 days ago
Verrica Pharmaceuticals Inc. ( VRCA ) Q3 2025 Earnings Call November 17, 2025 8:30 AM EST Company Participants Jayson Rieger - President, CEO & Director John Kirby - Interim Chief Financial Officer Conference Call Participants Kevin Gardner Stacy Ku - TD Cowen, Research Division Yuchen Ding - Jefferies LLC, Research Division John Todaro - Needham & Company, LLC, Research Division Brian Kemp Dol...
Neutral
GlobeNewsWire
6 days ago
–   Company reports $14.3 million in revenue in Q3'25, consisting of $3.6 million in YCANTH ® revenue and $10.7 million of license and collaboration revenue –
Neutral
GlobeNewsWire
11 days ago
– Exploratory Phase 2 analysis shows Verrica's novel oncolytic peptide, VP-315, reprograms the tumor microenvironment, increasing cytotoxic T-cell infiltration and reducing immunosuppressive T-regulatory cells – – Findings provide mechanistic immunologic support for clinical efficacy previously reported, including 97% calculated objective response rate and 51% complete histologic clearance rate...
More Verrica Pharmaceuticals Inc News

Company Profile

Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product VP-102, is a proprietary topical therapy used in common skin indications including Molluscum contagiosum and Verruca Vulgaris. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Head office United States
CEO Jayson Rieger
Employees 71
Founded 2013
Website verrica.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today